FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama

FDA vaccine advisory committee members voted 9-0 to recommend approval of Moderna’s mRNA flu vaccine, mRNA-1010, marking a significant shift after previous agency resistance and controversy.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed data on Moderna’s seasonal flu vaccine, mRNA-1010, which demonstrated approximately 27% higher efficacy than standard flu vaccines in adults aged 50 and older, based on a Phase 3 trial involving over 40,000 participants. A smaller trial with nearly 3,000 older adults showed the vaccine elicited stronger immune responses than high-dose flu vaccines, which are typically recommended for this age group.

The committee also noted that the vaccine’s safety profile was generally positive, with no significant safety concerns raised during the review. Prominent members praised the robustness of the data and highlighted the advantages of the mRNA platform, including rapid development and potential for better response to emerging strains. The vote followed a period of agency controversy, including a previous refusal by a Trump-era appointee to review Moderna’s filing, which was later reversed after public and scientific outcry.

Implications of the Committee’s Support for Moderna’s Vaccine

The committee’s unanimous support indicates strong scientific backing for Moderna’s mRNA flu vaccine, which could become a new tool in seasonal flu prevention. If approved by the FDA, it may offer improved efficacy and adaptability compared to traditional flu vaccines, potentially transforming flu vaccination strategies and pandemic preparedness. This approval could also reinforce the credibility of mRNA technology beyond COVID-19, highlighting its versatility and future potential.

Forbidden Facts: Government Deceit & Suppression About Brain Damage from Childhood Vaccines

AmazonView Latest Price

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Background on FDA Approval Process and Recent Controversies

Moderna’s mRNA-1010 vaccine has undergone extensive testing, with data showing promising efficacy and safety profiles. The vaccine’s review process was marked by controversy earlier this year, when a Trump-appointed FDA official rejected Moderna’s filing, citing concerns over trial design, despite backing from FDA scientists. This decision was reversed after widespread criticism, leading to the current review. The episode underscored ongoing political and ideological tensions within the FDA regarding vaccine approval processes and mRNA technology.

“They have very clear results that are very robust in terms of demonstrating that additional efficacy.”

— an anonymous VRBPAC member

Remaining Questions About Moderna’s Flu Vaccine Approval

It is not yet confirmed whether the FDA will approve the vaccine by the August 5 deadline. Additionally, the upcoming CDC review and recommendation process, which is critical for widespread adoption and insurance coverage, is currently facing delays due to legal challenges affecting the CDC’s advisory committee. The impact of these political and legal issues on the vaccine’s rollout remains uncertain.

Next Steps Toward Widespread Use of Moderna’s mRNA Flu Vaccine

The FDA is expected to make a final decision on approval by August 5. If approved, Moderna aims to release the vaccine later this year, pending CDC endorsement. The CDC’s Advisory Committee on Immunization Practices (ACIP) will then review the vaccine and issue recommendations. However, legal challenges to the CDC’s advisory process could delay or complicate this step, affecting the vaccine’s availability for the upcoming flu season.

Key Questions

When will the FDA decide on Moderna’s flu vaccine?

The FDA is expected to make a decision by August 5.

What are the potential benefits of this mRNA flu vaccine?

The vaccine has shown higher efficacy than standard flu vaccines and offers rapid adaptability to emerging strains, potentially improving seasonal flu prevention.

What legal or political challenges could affect the vaccine’s approval?

Legal challenges to the CDC’s advisory committee, currently under appeal, could delay or impact the recommendation process needed for widespread adoption.

Will this vaccine be available for the upcoming flu season?

If approved by the FDA and recommended by the CDC, Moderna plans to release the vaccine later this year, but delays in approval or recommendation could affect timing.

Source: Hacker News